 |
 |

Risk Factors for Repeatedly Reactive HIV-1 EIA and Indeterminate Western BlotsA Population-Based Case-Control Study
Connie L. Celum, MD, MPH;
Robert W. Coombs, MD, PhD;
Margie Jones, MA;
Victory Murphy, ARNP;
Lloyd Fisher, PhD;
Christopher Grant, PhD, DSc;
Lawrence Corey, MD;
Thomas Inui, ScM, MD;
Mark H. Wener, MD;
King K. Holmes, MD, PhD
Arch Intern Med. 1994;154(10):1129-1137.
Abstract
 |  |
Objective Causes of indeterminate results of Western blot testing (IWB) for human immunodeficiency virus (HIV) type 1 include seroconversion, HIV-2 cross-reactivity, and autoimmune disease, but most IWB results remain unexplained. This case-control study assessed risk factors for IWB results, including early HIV infection, other retroviral infection, autoantibodies, and other medical conditions.
Design Prospective study to determine HIV seroconversion rate, with a case-control design to assess other risk factors for IWB. Cases (persons with one or more repeatedly reactive HIV-1 enzyme immunoassay with IWB), their current sexual partners, and controls (persons with negative enzyme immunoassay and Western blot results) were recruited from blood banks, health department and prenatal clinics, and private providers in Washington and Oregon.
Results Of 244 cases enrolled, 206 were followed up for 6 months or longer, and six (3.0%; 95% confidence interval [CI], 0.7% to 5.3%) with recent HIV risk behaviors seroconverted. The Western blot banding patterns differed among groups; cases usually had p17 or p24 bands, while controls and cases' sexual partners usually had polymerase bands. Conditional logistic regression indicated that independent risk factors for IWB among male cases and controls were a tetanus booster in the past 2 years (odds ratio, 3.2; 95% CI, 1.2 to 8.6) and sexual contact with a prostitute (odds ratio, 3.0; 95% CI, 1.0 to 9.5). Independent risk factors for women were parity (odds ratio, 1.2;95%CI, 1.02 to 1.4) and autoantibodies, either rheumatoid factor or antinuclear antibodies (odds ratio, 2.3; 95% CI, 1.03 to 5.6). No cross-reactivity was detected with HIV-2, human T-lymphotrophic virus type 1, feline immunodeficiency or feline leukemia, or bovine immunodeficiency viruses.
Conclusions Evaluation of persons with reactive HIV-1 enzyme immunoassays and IWB should include an assessment of HIV risk and other possible risk factors, such as alloimmunization (ie, parity or recent immunization) or autoantibodies (ie, antinuclear antibodies and rheumatoid factor). The relationship of IWB among men who reported sex with prostitutes is intriguing and warrants further study.
(Arch Intern Med. 1994;154:1129-1137)
Author Affiliations
From the Departments of Medicine (Drs Celum, Coombs, Corey, Inui, Wener, and Holmes, and Ms Murphy), Laboratory Medicine (Drs Coombs, Corey, and Wener), and Biostatistics (Ms Jones and Dr Fisher), and the Center for AIDS Research (Ms Murphy and Dr Holmes), University of Washington, Seattle; and the Pacific Northwest Research Foundation, Seattle (Dr Grant). Dr Grant is now with Custom Monoclonals, Sacramento, Calif. Dr Inui is now with the Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, Mass.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Performance of an automated human immunodeficiency virus (HIV) antigen/antibody combined assay for prenatal screening for HIV infection in pregnant women
Garcia et al.
J Med Microbiol 2009;58:1529-1530.
FULL TEXT
Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United States
Owen et al.
J. Clin. Microbiol. 2008;46:1588-1595.
ABSTRACT
| FULL TEXT
Frequency, Causes, and New Challenges of Indeterminate Results in Western Blot Confirmatory Testing for Antibodies to Human Immunodeficiency Virus
Guan
CVI 2007;14:649-659.
FULL TEXT
Innate and Adaptive Mucosal Immunity in Protection against HIV Infection
Bergmeier and Lehner
ADR 2006;19:21-28.
ABSTRACT
| FULL TEXT
Mucosal alloimmunization elicits T-cell proliferation, CC chemokines, CCR5 antibodies and inhibition of simian immunodeficiency virus infectivity
Bergmeier et al.
J. Gen. Virol. 2005;86:2231-2238.
ABSTRACT
| FULL TEXT
Screening for HIV: Recommendation Statement
U.S. Preventive Services Task Force*
ANN INTERN MED 2005;143:32-37.
ABSTRACT
| FULL TEXT
Prenatal Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou et al.
ANN INTERN MED 2005;143:38-54.
ABSTRACT
| FULL TEXT
Protein Bead Array for the Detection of HIV-1 Antibodies from Fresh Plasma and Dried-Blood-Spot Specimens
Faucher et al.
Clin. Chem. 2004;50:1250-1253.
FULL TEXT
Evaluation of the Rapid Immunoassay Determine HIV 1/2 for Detection of Antibodies to Human Immunodeficiency Virus Types 1 and 2
van den Berk et al.
J. Clin. Microbiol. 2003;41:3868-3869.
ABSTRACT
| FULL TEXT
False-Positive and Indeterminate Human Immunodeficiency Virus Test Results in Pregnant Women
Doran and Parra
Arch Fam Med 2000;9:924-929.
ABSTRACT
| FULL TEXT
Report of a False-Positive HIV Test Result and the Potential Use of Additional Tests in Establishing HIV Serostatus
Mylonakis et al.
Arch Intern Med 2000;160:2386-2388.
ABSTRACT
| FULL TEXT
|